Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.

[1]  J. Pruvo,et al.  Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[2]  B. Chwalisz,et al.  MRI Characteristics of NMO, MOG and MS Related Optic Neuritis , 2020, Seminars in ophthalmology.

[3]  S. Saidha,et al.  AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.

[4]  A. Vosoughi,et al.  Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment. , 2020, Multiple sclerosis and related disorders.

[5]  D. Hodge,et al.  Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. , 2020, American journal of ophthalmology.

[6]  Jacqueline Palace,et al.  Prodromal headache in MOG-antibody positive optic neuritis. , 2020, Multiple sclerosis and related disorders.

[7]  John J. Chen,et al.  Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis , 2019, Current Neurology and Neuroscience Reports.

[8]  John J. Chen,et al.  Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. , 2019, Current opinion in neurology.

[9]  M. Bach,et al.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[10]  T. Siepman,et al.  The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults , 2019, Multiple sclerosis.

[11]  Quangang Xu,et al.  Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China , 2019, Journal of the Neurological Sciences.

[12]  M. Etemadifar,et al.  Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome. , 2019, Multiple sclerosis and related disorders.

[13]  Quangang Xu,et al.  The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis , 2019, Journal of the Neurological Sciences.

[14]  B. Weinshenker,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.

[15]  J. A. Fraser,et al.  Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial , 2018, JAMA neurology.

[16]  John J. Chen,et al.  Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial , 2018, JAMA ophthalmology.

[17]  T. Kezuka,et al.  Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis , 2018, Japanese Journal of Ophthalmology.

[18]  Jacqueline Palace,et al.  Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.

[19]  V. Fung,et al.  Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  A. Petzold,et al.  Time is vision in recurrent optic neuritis , 2017, Brain Research.

[21]  B. Brochet,et al.  Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France , 2017, Journal of Neurology.

[22]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.

[23]  T. Nakazawa,et al.  Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica , 2016, Journal of Neuroimmunology.

[24]  V. Fung,et al.  Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis , 2016, Multiple sclerosis.

[25]  T. Nakazawa,et al.  MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  M. Kupersmith,et al.  Optic neuritis: correlation of pain and magnetic resonance imaging. , 2003, Ophthalmology.

[27]  R. Beck,et al.  Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. , 1993, Archives of ophthalmology.

[28]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[29]  John J. Chen,et al.  Optic Neuritis In the Era of Biomarkers. , 2019, Survey of ophthalmology.

[30]  Xinghuai Sun,et al.  Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China , 2017, Journal of Neurology.